Long-term Outcomes of Oral Decitabine/Cedazuridine Plus Venetoclax in Older or Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia
Posted inClinical Updates Hematology-Oncology news

Long-term Outcomes of Oral Decitabine/Cedazuridine Plus Venetoclax in Older or Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Oral decitabine/cedazuridine plus venetoclax provides an effective, fully oral frontline therapy for older or unfit patients with AML, showing encouraging response rates and manageable safety with long-term follow-up, highlighting particular challenges in secondary AML.
Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCT
Posted inHematology-Oncology news Oncology

Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCT

Fludarabine, cyclophosphamide, and low-dose TBI combined with post-transplant cyclophosphamide provide a safe and effective single platform for haploidentical and unrelated donor allo-SCT in older AML/MDS patients, showing favorable survival and GVHD outcomes.
Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS
Posted inHematology-Oncology news Oncology

Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS

A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and encouraging early survival outcomes.
Targeting the Glycan Signature: Oncofetal Chondroitin Sulfate as a Selective Vulnerability in Acute Myeloid Leukemia
Posted inClinical Updates Hematology-Oncology news Pathology & Lab Medicine

Targeting the Glycan Signature: Oncofetal Chondroitin Sulfate as a Selective Vulnerability in Acute Myeloid Leukemia

This review explores oncofetal chondroitin sulfate (ofCS) as a revolutionary AML target. Unlike traditional antigens, ofCS is absent in normal bone marrow, allowing antibody-drug conjugates to eliminate leukemia cells with minimal hematotoxicity in preclinical models.
Metformin Triggers Ferroptosis in AML Through Lipid Remodeling: A Repurposing Opportunity for Metabolic Subtypes
Posted inHematology-Oncology news

Metformin Triggers Ferroptosis in AML Through Lipid Remodeling: A Repurposing Opportunity for Metabolic Subtypes

A new ex vivo study shows metformin induces ROS-driven ferroptosis in acute myeloid leukemia (AML), particularly in samples with altered lipid metabolism (IDH2, FLT3 mutations). Lipidomic remodeling, CD36-mediated fatty acid uptake, and DGAT1 activity determine sensitivity—suggesting biomarker-guided repurposing strategies and combination approaches.
DAGO2 (daunorubicin/cytarabine + fractionated gemtuzumab) Outperforms CPX‑351 in Older Adults with Non‑Adverse‑Risk AML: NCRI AML18 Results
Posted inHematology-Oncology news

DAGO2 (daunorubicin/cytarabine + fractionated gemtuzumab) Outperforms CPX‑351 in Older Adults with Non‑Adverse‑Risk AML: NCRI AML18 Results

In older adults (≥60 years) with non‑adverse‑risk AML enrolled in NCRI AML18, daunorubicin/cytarabine plus fractionated gemtuzumab (DAGO2) produced higher early MRD‑negative CR rates and superior 3‑year EFS and OS versus CPX‑351, with particular molecular subgroups showing no benefit or harm from CPX‑351.